Magazine

Meet National Stock Exchange of Australia Managing Director and CEO Max Cunningham

Tell us a bit about yourself. What was your journey to the NSXA?

I’ve been in capital markets for over 30 years. I was a foundation employee when Macquarie Equities opened a retail broking business in Australia in 1994 and was sent to London with Macquarie in 1997 to help build out the U.K. institutional business. 

In 2004, I moved to New York to perform a similar role with Goldman Sachs, before returning to Australia to head up Goldman’s capital markets business in 2008. I shifted to ASX and the exchange world in 2013, where we built a strong franchise around tech listings, including achieving great success in the U.S., Israel, and Ireland. 

Exchanges play an important role in helping companies raise capital, and I believe that role had been increasingly neglected in Australia. The National Stock Exchange of Australia (NSXA) was attractive to me as an underutilized public market with a valuable listings licence. I saw a great opportunity to rebuild the NSXA as a competitor in the venture and start-up space, very similar to CSE’s successful execution in Canada.

For those of us who are unfamiliar with the NSXA, can you please provide a bit of background on the exchange, as well as some context around the current challenges and opportunities for public companies in the Australian capital markets?

The National Stock Exchange of Australia has been around in various guises for over a century. Part of its history includes the Bendigo Stock Exchange, formed in the 1860s to fund the Victorian gold rush. This century, NSXA has led many innovations, including tokenizing wine units in 2002, trading taxi plates in 2006, and, more recently, operating a market for agricultural cooperatives to trade shares.

As CEO, what is your vision for NSXA over the next few years? For this partnership?

Our goal is simply to innovate and compete. On the innovation front, we intend to invest in cutting-edge technology to improve trading capability, provide additional services, and expand our listings offering. Competition is something you create as an exchange, and the reality is that small miners, pre-revenue tech, and life sciences companies are increasingly finding it difficult to IPO in Australia, and we can assist with that. The same applies to junior explorers listed in Canada.

Our partnership with CSE will assist on all fronts. It offers experience and expertise in a similar market, provides technology and marketing support, and a great existing network of issuers to call upon. Moreover, Australians and Canadians are natural allies. The NSXA and CSE teams have clicked together very well. That’s obviously great for our staff, but it’s also beneficial for our customers and other stakeholders.

The collaboration opens the door for, among other things, dual listings. What are the benefits for retail investors and public companies in both Australia and Canada?

In reality, we have similar markets and economies, with large pension plans and individual investors looking at opportunities, especially in the mining sector. In my view, Canada and Australia have slightly different investment, risk, and interest rates cycles, with Canada slightly skewed toward the U.S. and Australia toward Asia. This often presents “valuation arbitrage” that companies can potentially benefit from by being listed in both markets. The prospect is exciting.

Looking ahead, how do you expect Australia’s capital markets landscape will evolve, especially as it relates to international opportunities?

Australian pension pools are growing exponentially, and there is a big drive to invest in local tech and keep those businesses local, especially their intellectual property. This combination should see more international opportunities to dual list so as to take advantage of that combo. Indeed, the Australian government has committed AUD$1 trillion of investment in the U.S. over the next decade. There’s no reason why a large part of that can’t be realized through dual listing opportunities. As I look ahead, I see a dynamic and healthy future.

CSE Issuer Stories, Magazine

A Unique Approach to Ultra-Pure Production Could Spur the Wider Adoption Needed for Graphene to Truly Take Off

Investors are constantly on the hunt for disruptive products that completely change an industry’s dynamics. Disrupting the approach to manufacturing a game-changing product thus seems like taking things to an even higher level.

That is what HydroGraph Clean Power (CSE:HG; OTCQB:HGRAF) has been working on since 2017, when the company was formed to pursue the production of graphene in a way that resulted in higher purity, was more cost-effective, and more environmentally friendly than conventional methods.

Fast-forward to 2025 and HydroGraph has reached its objective, with a readily scalable process that yields high-quality graphene while adhering to the founding team’s tenets.

Graphene is perhaps best described as a super-material. Many times stronger than steel, it is also a highly efficient conductor of electricity and heat, impermeable, and very flexible, among other qualities. The process of incorporating it into products can require specialized knowledge, but it still has found a home in a long list of items, with composites, electronics, and biomedical products among the categories tipped to lead future applications.

HydroGraph’s core technology is its patented detonation synthesis process, which is quite a departure from methods that begin with graphite from the ground. Instead, HydroGraph detonates hydrocarbon gases using acetylene and oxygen to generate synthetic graphene by turning the gas into a powder.

One aspect of the process that makes it unique, according to the company, is its simplicity. Conducting the detonation process with high-purity feedstock yields graphene with a purity level on the order of 99.8%. Consistency is another competitive advantage for HydroGraph, as the company has been able to produce a virtually identical product each time it has scaled up output.

And changing the details on the input side can produce different graphene types to meet the particular needs of a given customer.

Technologies like these need protection, and in this regard HydroGraph holds three patents at present, with another eight pending.

“A number of companies have tried to go around our patents and everything has been rejected by the U.S. Patent Office, so we feel strongly about our position in the market,” says HydroGraph Clean Power Chief Executive Officer Kjirstin Breure.

Breure, who joined the company as its Chief Operating Officer in 2020 before becoming CEO in 2024, holds an MSc in Materials Science and Engineering from Arizona State University and has spent over a decade involved with emerging technologies in the commercial sector, including machine learning, data analytics, and blockchain.

Commercialization of HydroGraph’s graphene is already underway, with more than 60 entities in various stages of testing it for potential inclusion in a wide range of products and industries.

One of those, Hawkeye Biomedical, is using HydroGraph’s graphene in its Lung Enzyme Activity Profile (LEAP) lung cancer biosensors. And in late September, HydroGraph announced a letter of intent with SEADAR Technologies, a developer of subsea sensing and surveillance solutions, to integrate HydroGraph’s graphene materials and coating technologies into current and future SEADAR undersea products.

Breure notes that the average development cycle for its customers is about 18 months. First is lab-scale testing, which leads to industrial trials where a potential customer experiments with HydroGraph’s materials. Assuming everything goes well, contract negotiation is the next step.

An important venue for interacting with potential clients in the graphene industry is the Graphene Engineering Innovation Centre (GEIC) at the University of Manchester. HydroGraph has its own laboratory at the GEIC, which has established itself as a hub for companies looking to integrate graphene into their products. With deep expertise on site and all the right equipment, the GEIC is the perfect location for graphene suppliers and users to explore real business relationships.

Current production capacity is 10 tons per year and new production units, in the form of the company’s patented Hyperion detonation chamber, can be built and brought onstream in as little as two to three months.

HydroGraph’s first commercial unit, a 13,000 square foot facility located in Manhattan, Kansas, started production in 2022. The company’s second production facility will be established in Texas, in part because that state is one of the best places to source the acetylene used in the detonation process.

Scaling up on the revenue generation front could feed quickly to the bottom line, as HydroGraph estimates that an outlay of US$10 million to US$15 million on production can generate more than $100 million in sales.

With the ability to quickly increase production capacity and a healthy pipeline of potential customers, it is reasonable to expect new developments coming to light before long.

“We will be announcing the gas partner that we are working with for a large-scale production facility where we have negotiated pipeline access for acetylene, and we are looking forward to announcing a relationship with the U.S. military,” Breure says.

Breure adds that HydroGraph is planning to provide an update on the status of its submission to the U.S. Environmental Protection Agency and that contract announcements emerging from the company’s commercial pipeline are likely.

“We have between 10 and 15 clients that are really in that last stage that could convert into revenue within the next year,” Breure says, adding that the company has generated “small amounts” of revenue thus far but expects a more significant revenue stream to be “kicking in next year.”

This story was featured in Canadian Securities Exchange Magazine.

Learn more about HydroGraph Clean Power https://hydrograph.com/.

CSE Issuer Stories, Magazine

A Mathematical Approach to Location Assessment Finds Applications Across a Wide Spectrum

They were a novelty not that many years ago, but today drones are growing quickly in popularity and importance, used for everything from documentary filmmaking to surveillance and payload delivery on modern battlefields.

For military applications, undermining the effectiveness of a drone by denying it use of critical data and control inputs is something all major armed forces are likely working on. As such, the more independent one can make a drone, the greater its chance to be effective today and in the environments of the future.

Sparc AI (CSE:SPAI; OTCQB:SPAIF) has developed a solution that enables drones to assess object location without the use of GPS, radar, or other inputs that most such devices currently rely on. Its technology is ready to commercialize, and other innovations for drone operator control platforms are just around the corner.

Canadian Securities Exchange Magazine spoke recently with Sparc Al Chief Executive Officer Anoosh Manzoori about the technology’s capabilities, practical applications, and the status of commercialization efforts. 

Sparc AI’s technology uses sophisticated algorithms to measure the location and distance to any object on land or water, with military drones being an important application. How would you define the company’s current objectives?

Our core mission is built around technologies that allow products to work out in the field without GPS.

Interruption to GPS is a real challenge for both defence and commercial applications. There are something like 34 GPS satellites, and you need four of them to record just one location. The receiver connections to these satellites can be compromised, leading to a GPS-denied environment.

Looking at an object that is 5 kilometres away, for example, and determining its geocoordinates and distance without GPS, or any other sensor, is the crux of what we are trying to solve.

That would be our target-acquisition system, and we have another product that is coming that adds intelligence to that platform. It is all operating in a covert environment without GPS.

With drones, weight is an issue, as an operator often wants them to fly long distances or loiter for extended periods. What equipment does Sparc AI attach to drones to facilitate your solution?

Our solution is completely software-based; the telemetry data that is already with the drone is what we use. We need to know the height of the drone. And all drones have a barometer so they can measure air pressure as they move up in the sky. We need to know the angle of the camera pitch in terms of its line of sight. We also need to know the heading or the compass of where the drone is pointing.

What we are doing is mathematically creating a representation of the device in the air relative to the terrain and where it sits. It becomes spatially aware of where it is and where it is pointing, and we can then do a representation of where it is looking and calculate the distance and geolocation.

We don’t use any sensors. We don’t use lasers, lidar, radar, or image recognition software. Although we use the camera, it is already on the drone for the benefit of the operator to see what they are looking at.

We are installed on a Parrot ANAFI drone, a military drone. It is a 500-gram drone, so if we were to put more equipment on it, you would not be able to fly the device.

Because we are software-based and covert, there is no signature emitting from the drone, and nobody knows we are doing any targeting. We save on payloads, weight, and battery.

What is the maximum distance Sparc AI’s technology can measure?

Range really comes down to the ability for the operator to see the target. On the ANAFI drone, for example, the camera enables us to zoom in on a target. We have not seen any limitations on the range and have tested as far as 50 kilometres. We are limited based on how much we can see.

With alternative technologies that might be using a laser system, radar, or lidar, the farther away the object becomes, the less accurate it generally is. Think of a laser beam that becomes more like a cone as it goes farther from its source. These technologies are also detectable and not covert.

Mathematically, there are no limitations in terms of how far the technology would work. It also works on both land and water.

What is the competitive landscape in this market? Technology with military applications is in intense development around the world.

In the military sense, there is a category of products called the target-acquisition system. They typically weigh about 20 kilograms to 25 kilograms and fit a soldier’s backpack. They require a bit of setting up, have to be installed on a tripod, and come with a cable about 25 metres long that connects to a tablet.

The solider needs to install it, position the device, then go and hide somewhere with the tablet to control the system. The reason they need to do that is because the system has a laser – and sometimes radar – on it, so it emits a signature. Basically, when you are looking at your adversary, you then become detectable, and they can start to look back at you. You start to put yourself at risk the moment you set this up.

The system is also quite expensive and requires a lot of energy, so soldiers typically carry extra battery packs.

The alternative is to put the equipment onto a drone. That means the drone is big, quite expensive, and will send a signature back to the enemy.

The way Sparc AI works, because it is completely software-based, it can be used on any device. The Parrot ANAFI is a drone very much used on the edge of the battlefield, and with Sparc AI you could do your target-acquisition rapidly, without any detection.

The software is installed on the controller, so we are not using any resources of the drone. We have also developed an extension where we are able to navigate the drone autonomously using purely the target-acquisition system to record the location and coordinates for navigation.

Are there other markets in addition to military applications?

Another market is search and rescue, where you identify the location of assets or people during emergencies. The technology was sold to one of the largest telecommunications companies, and it was installed on fixed cameras rather than drones. Think of an old pipeline that requires maintenance that is located in GPS-denied environments.

Sparc AI’s technology is very specialized. Can you discuss your team with us?

We have two people who are ex-military personnel, one of whom had leading roles in special forces here in Australia. So, both have experience in the defence sector that not only commercially helps open doors but also enables us to better tailor our product for the defence market.

We also have two directors who are very experienced in commerce and finance and dealing with technology companies.

As for myself, I built one of the largest cloud hosting companies in Australia before exiting and have been an active investor for the past 25 years. I’m quite technical and have made significant contributions to our technology and source code.

Where are you in terms of commercialization?

We have a couple of approaches. One is speaking directly to defence departments here in Australia, as well as in Canada and the United States. These are often through referrals and people we know in the industry, and we are conducting regular live demonstrations of the product.

We are in discussions with contractors that supply products directly to defence, and there is an opportunity for Sparc AI to be bundled as part of an existing offering.

We have also been accepted into the Parrot Technology Solutions Program. Parrot sells their drone primarily to defence and first responders. They have an indirect sales model where they sell their product through distributors and resellers around the world, and they have a program where they invite companies integrated into the Parrot platform to provide additional capabilities to plug into that distribution and gain potential customers.

We are also discussing with partners here what they call loitering solutions, which are solutions on the edge of land and water for surveillance and situational awareness in coastal areas.

Is there anything else you would like to add?

One thing that is quite important for this type of business is capability, so the more capability and intellectual property we build into the product, the closer it brings us to being able to get commercial contracts and build value for the company in terms of possibly being acquired. There is a lot of new capability that we have been working on and will be rolling out soon. We have made some announcements around it already, but there is more coming to elevate the capability of this product.

This story was featured in Canadian Securities Exchange Magazine.

Learn more about Sparc AI https://sparcai.co/home.

CSE Issuer Stories, Magazine

Epilepsy Drug in Phase II Trials and Peer Success Combine to Fuel a Standout Year

For three decades, central nervous system (CNS) drug development was a tough space for investors, scarred by failed bets on Alzheimer’s disease, plateauing first-generation antidepressants, and setbacks in safety and efficacy. 

But advances in receptor-selective chemistry and so-called “biased agonism” – steering toward therapeutic pathways and away from areas that cause side effects – are reviving interest in the field. 

Successes such as esketamine for depression or cannabinoids for epilepsy have shown that carefully targeted mechanisms can deliver commercial as well as clinical breakthroughs. 

That shift is fuelling a new wave of investment in CNS-focused solutions, with several biotech companies absorbed by larger players in recent years. 

One of the companies that illustrates this shift is Bright Minds Biosciences (CSE:DRUG), which is now in Stage II trials for its lead epilepsy drug. The company’s dramatic share performance in the past 12 months, involving appreciation of approximately 5,000%, is why investors come to the biotech space. Bright Minds has certainly delivered.

The company was founded seven years ago by former investment banker and current Chief Executive Officer, Ian McDonald, Dr. Alan Kozikowski, a pharmaceutical entrepreneur and one of the most prolific researchers in psychedelic drug discovery, and Dr. Gideon Shapiro, a veteran of CNS drug discovery with senior roles at Sandoz-Novartis and Forum.

Bright Minds is seeking to prove that finely tuned serotonin-targeting drugs can succeed where other compounds have fallen short. 

Its lead compound, BMB-101, is being tested with two forms of childhood epilepsy, with data expected around the end of this year.

The scientific premise is straightforward but ambitious: BMB-101 selectively activates the serotonin 5-HT2C receptor, known as 2C, a target known to influence neuronal activity.

Activating that receptor indirectly boosts levels of the neurotransmitter gamma-aminobutyric acid (GABA), which calms neuronal pathways to aid normal brain function and helps prevent the electrical discharges that result in epilepsy.

Several other medicines also target 2C, but BMB-101 avoids closely related receptors linked to undesirable effects. 

Past drugs in this space, including the diet drug fenfluramine, were plagued by serious cardiac and psychedelic side effects because they also activated the 2B and 2A receptors. 

Bright Minds’ molecule is designed to bypass those problems and also to avoid the desensitization and tolerance build-up that has undermined many chronic CNS therapies.

“Our compound is an advancement from that – a safer version that doesn’t have the 2A and 2B liabilities,” says McDonald.

BMB-101, which has IP protection out to 2041, is in Phase II studies for two types of epilepsy.

One is developmental epileptic encephalopathies, catastrophic epilepsies which begin in childhood and continue throughout life, with high mortality rates and patients who generally experience a range of problems stemming from the epilepsy.

“We’re also looking at a separate population with absence epilepsy, which isn’t very well treated at the moment,” says McDonald. 

“Only a couple of therapies have been approved for it, and there’s a significant unmet need in that patient population.”

He says these current trials are due to produce results around the end of the year.

An upswing in M&A in recent years suggests that large pharmaceutical groups are willing to pay for validated serotonin 2C assets.

Zogenix, which commercialised fenfluramine, was acquired by Belgium’s UCB for up to US$1.9 billion in 2021; GW Pharmaceuticals was bought by Jazz Pharmaceuticals for US$7.2 billion in the same year; in October 2024, Denmark’s Lundbeck paid US$2.6 billion for Longboard Pharmaceuticals.

This latter deal was potentially the most relevant for Bright Minds, as Longboard’s compound operates with a similar serotonin 2C mechanism, and it had recently completed its Phase II study when the deal was done.

McDonald believes his lead compound could be superior, with high selectivity and applications in treatment-resistant epilepsy. 

“In chronic dosing situations these other compounds often develop tolerance, but our molecule is designed to minimize or eliminate that.”

Within the serotonin 2C receptor there are different signalling pathways. 

BMB-101 works exclusively via the pathway responsible for the therapeutic effect, known as the Gq-protein signalling pathway, and avoids the beta-arrestin pathway, which is responsible for tolerance development.

In earlier tests, the molecule demonstrated efficacy in numerous models of generalized seizures.

While McDonald says it is “potentially a best-in-class drug,” he acknowledges that a lot can go wrong in clinical trials. “The difference here is we know the mechanism works and we know our drug is hitting it.”

The reason Longboard was bought even before it had started Phase III studies, and that Bright Minds shares skyrocketed around 1,500% in the same week as that deal, is that epilepsy trials have strong predictability. 

“If you succeed in Phase II, you’re likely to succeed in Phase III,” says McDonald. “Also, fenfluramine was proven to work, and Longboard’s compound was superior. It was lower risk than many other drugs at that stage. Our compound works on the same mechanism, but we have the biased agonism feature against tolerance development – and ours is more convenient too. Longboard’s compound must be given three times a day and refrigerated throughout. We don’t have those issues.”

While some investors may be crossing their fingers for suitors to swoop after Phase II, the company has a cash runway through to 2027 to take the molecule to the edge of commercialization.

There is also a wider portfolio of intellectual property in the pipeline in neurology and psychiatry, with multiple programs of interest, all built off the strong medicinal chemistry background of its co-founders, with compounds that accentuate the benefits of the mechanism while avoiding negative side effects. 

One indication in the same 2C space is a debilitating disease called Prader-Willi syndrome, which has around 10,000 patients in the U.S. and starts in childhood, with patients generally having a developmental disability and experiencing some neuropsychiatric symptoms.

Others include BMB-201, a non-hallucinogenic psychoplastogen for treatment-resistant depression.

Those additional programs may offer upside optionality, but the company’s value will be determined by whether BMB-101 delivers the pivotal data investors are betting on.

If BMB-101’s data lives up to McDonald’s billing, the company could suddenly find itself on more than a few corporate shopping lists.

This story was featured in Canadian Securities Exchange Magazine.

Learn more about Bright Minds Biosciences https://brightmindsbio.com/.

CSE Issuer Stories, Magazine

Recent Earnings Results Validate Cannabis and Alcohol Strategy

North America’s legal cannabis industry is still in the early stages of development, shaped by complex regulation, high taxes, and fierce competition – pressures that only the most capable management teams can navigate.

That dynamic is clear when speaking with SNDL (CSE:SNDL) Chief Executive Officer Zachary George, who anticipated how the industry would evolve, the points of differentiation that would matter, and how businesses would need to steer through the turbulence.

George knew the value of a long-term perspective. Inheriting Canada’s largest, but non-competitive, indoor cultivation facility, he worked to reshape a debt-laden, unprofitable business into a retail-forward regulated products model, adding alcohol as a stable cash flow anchor. The move gave his cannabis operations runway to mature, and the results are becoming clear: earlier this year, SNDL posted its first quarter of positive operating and net profit.

Canadian Securities Exchange Magazine spoke with George recently about SNDL’s formative years, his philosophy for the business, and medium-term expansion plans.

SNDL has built a successful cannabis business within a broader overall product portfolio. Where did this idea come from and what were some of the important milestones in the early days?

The business as it stands today was born out of a deep restructuring process. Once we were on the other side of the restructuring, we sought to build a diversified business model with two strategic pillars.

The first pillar was a vertical cannabis model, the likes of which did not exist in Canada. The second pillar was a financing business that would enable us to, in a compliant manner, invest in U.S. operators by being a passive supplier of credit, without running afoul of the restrictions that exist for Nasdaq-listed companies when it comes to what we call “plant-touching” operations in the United States.

That evolution took a number of twists and turns. Our first foray into retail happened with the acquisition of Spiritleaf in Canada in July of 2021.

Later that year, we were approached by Nova, the company behind discount banner Value Buds, which had quickly become a disruptive force. At the time, Alcanna, Western Canada’s largest private market liquor retailer, owned 63% of Nova. From a sum-of-the-parts perspective, it made more sense to acquire the parent company than to pay a premium for the subsidiary. The deal also gave us access to a leadership team with decades of regulated product retail experience. Many of the same value and convenience themes that drive consumer behaviour in alcohol are directly analogous in cannabis.

The scale that came from the Alcanna acquisition was critical to our model. As an SEC registrant subject to Sarbanes-Oxley Act requirements, we are subject to some of the most stringent financial reporting and internal control requirements on the planet. Given the costs related to these requirements, playing small was not an option, and we had to do something at scale. The liquor business contributed significant free cash flow to the overall model, which helped to mitigate these costs.

Let’s look at the business portfolio, which is almost evenly balanced between liquor retail and a multi-faceted cannabis business. Can you walk us through the liquor side first and outline its competitive advantages? 

SNDL holds significant market share in Alberta and a strong presence in British Columbia. However, each province presents unique regulatory challenges that shape our strategy.

When you talk about competitive advantages on the liquor side, I would point immediately to the success of the Wine and Beyond model. Building a capital-intensive retail model requires strong supply chain management and the ability to seize inventory opportunities in a decisive manner. In our Wine and Beyond locations, consumers can choose from more than 6,000 SKUs, and that breadth has really resonated. Our big box format stands in stark contrast to the consumer experience available in Ontario’s LCBO locations. We are seeing the model materially outperform more limited, convenience-focused formats.

We are expanding that part of the business and are excited to be opening another two new Wine and Beyond locations in Saskatchewan and a third in Calgary in the coming months.

On the cannabis side, you have a hybrid, vertically integrated model. Tell us about the structure and the thinking behind it.

A couple of observations are important. Canada’s provincial cannabis regulations are inconsistent, with some even contradicting one another. This dynamic creates stubborn supply chain inefficiencies that are anti-business and a disservice to the provinces, operators, and consumers alike.

In certain provinces, retail sales are managed by private operators working within a tightly regulated framework, while in others they are controlled and managed exclusively by the government through crown corporations. Of those provinces permitting private operators, some allow for full vertical integration, while others bar or limit licensed producers (LPs) from retail ownership. In British Columbia’s hybrid framework, private retail operators like us are capped at eight retail locations, while the province competes against us with over 40 of its own, and other operators skirt these regulations with complex ownership structures. In Ontario, a licensed producer is prohibited from owning more than 20% of a retail operator, while regulations in the Prairies allow for vertically integrated structures.

Provincial fiefdoms within crown corporations have preserved inefficiencies while failing to prioritize important public goods such as the optimization of consumption-based tax revenues and consumer safety. At the core of these issues is a question as to whether Canadians believe that their tax dollars should be used by provincial governments to directly manage consumer-facing retail operations.     

This is a departure from conventional consumer packaged goods (CPG) where brand awareness, efficient manufacturing, and clear routes to market can drive access to broad growth across a national market. The inherent inefficiencies in Canadian cannabis must be carefully managed. Instead of complaining about poor decision-making and weak enforcement by regulators and government bodies, we are directly involved in lobbying for rational reform. The steep and rocky path in the sector will ensure that very few competitors can survive. We are built for the climb.

Why did you choose a vertical structure?

With a mandate from our board to build a global cannabis business, we observed that in mature markets in the United States, the vertical operators in limited licence markets were by far the most profitable. Further, Health Canada’s restrictions and prohibitions on the marketing of branded products were a clear hindrance to building brand resonance with consumers. In sharp contrast to the regulation applied to alcoholic beverages, even something as simple as the depiction of a mountain on packaging, or the outline of an animal form, can draw fines and demands for the recall of products.  

In today’s marketplace, regulated brick-and-mortar retail is the best place to own the consumer relationship. E-commerce solutions have also been stunted by regulation, further reinforcing this dynamic, although we expect this to evolve positively in the future. 

In the early years, we saw a proliferation of products where brands themselves were being commoditized. We have the data from tens of millions of consumer transactions and know exactly where repurchase rates are. This data continues to show a strong willingness by the consumer to trial and switch products.

This dynamic created a strong desire to stay out of the fight among producers over whose pre-roll or flower strain was better. My focus was on building a platform that could track and adapt to consumer trends over time. Rather than competing in a sea of sameness with other LPs, I wanted to partner with them, helping to distribute and even manufacture some of their most successful products.

In doing so, we shifted from competing on products to competing on capability – building a platform that could support both our own brands and those of our partners. You will see our owned and co-manufactured brands in competitive retail, and you will see competitive suppliers dominate shelf space in our owned and managed retail network. We have a large B2B or co-manufacturing business building products for other LPs and have built quality products for most of the top 20 LPs in Canada today. We have automated manufacturing capabilities in every relevant product segment, including infused beverages, edibles, pre-rolls, flower, extracts, and vapes.

Let’s talk about performance. The second quarter of 2025 was SNDL’s first profitable quarter. What were some of the highlights?

Understanding the backdrop is really important. I am very proud of our team. Over the past five years, we have been able to grow our revenue base by over 1,500%. We have one of the cleanest balance sheets in the sector, with no debt and approximately $200 million in unrestricted cash to drive strategic investments. Last year was the first full calendar year that we generated free cash flow. We have hit new milestones and records almost every quarter for the past 14 quarters. In our most recent second quarter, we generated our first quarter of positive operating and net income.

We have announced the acquisition of a 32-door retail portfolio that we are working to close in October and have significant embedded growth coming from our credit investments. Some of those positions are being equitized and may be consolidated in the future.

We have also managed to buck some of the negative trends in alcohol consumption, which is a credit to the strong execution capabilities of our team.

As you look to the near and medium terms, how do you shape strategy given the competitive landscape and the opportunities afforded by your business lines?

We put together a three-year strategic plan supported by our board, and our priorities are clear. Our number one priority is to continue to grow our Canadian retail cannabis and liquor businesses. Second would be the stabilization and investment in U.S. businesses we have exposure to, including operations in Florida, Massachusetts, Texas, and Michigan, all of which have unique and distinct regulatory frameworks. Third would be international. We are excited to be landing finished goods in the U.K. and shipping wholesale flower to several international medical markets. Our segment leaders are focused on delivering profitable growth in our alcohol and cannabis segments in 2026 and beyond.

This story was featured in Canadian Securities Exchange Magazine.

Learn more about SNDL https://www.sndl.com/.

CSE Issuer Stories, Magazine

A Personal Mission to Reprogram the Human Immune Response to Cancer

Often when we discuss life sciences, particularly as investors, the human element gets lost. The focus tends to be on the pipeline, clinical and preclinical progress, data, efficacy, cash runway, and addressable market. These and other inputs can be plugged into a model to provide insight into a company’s chance of success.

But this process ignores the point of the business: to help people recover, to fight illness, or in the case of late-stage disease, to add months or perhaps years to life. It also disregards the human sacrifice along the way. This is particularly true in cancer research, where end-of-life patients often volunteer in the hope that the next generation benefits from their experience.

For ME Therapeutics (CSE:METX; OTCPK:METXF) Chief Executive Officer Salim Dhanji, the metrics that make the investment case are important but not the real litmus test. Rather, he is driven by a desire to change outcomes for people. Dhanji notes that he is at the stage in life where friends and family are succumbing to the ailments of middle and later years. The determination and passion that drive him are plain to see.

A researcher at heart, he wants a real, human dimension to his team’s work. “To use new technologies, and our knowledge of these technologies to create drugs to treat cancer patients in a personalized way, is something that really motivates me,” Dhanji tells Canadian Securities Exchange Magazine. “You’re starting to see that [in other areas of research], and I think that’s the really exciting bit; where you can potentially bring about real change.”

Dhanji earned his Bachelor of Science and PhD at the University of British Columbia and has more than 20 scientific publications and patents relating to cancer, autoimmunity, and inflammation to his credit. ME Therapeutics, founded in 2014, reflects that body of work.

The ME component of the company’s name stands for “myeloid enhancement,” a clue to the science behind its three drug development and discovery programs. Put simply, this involves reprogramming the immune response against cancer. The team is tackling one of oncology’s toughest problems: how cancers hijack the body’s own immune cells to shield themselves from attack.

ME Therapeutics is developing drugs that reprogram so-called myeloid cells. These normally regulate immune responses but in tumors often act as double agents, suppressing cancer-killing T cells and creating a cocoon around malignant tissue. Rather than designing medicines to target a specific mutation, ME Therapeutics is targeting the immune environment itself. That means its drugs could be used across many cancer types, much like today’s blockbuster immunotherapies such as Merck’s Keytruda or Bristol Myers Squibb’s Opdivo.

The company is working on three fronts. One program delivers synthetic messenger RNA into tumors to coax immune cells into action and turn “cold” tumors into “hot” ones that draw an immune response. A second program engineers in vivo chimeric antigen receptors (CARs) into immune cells directly inside the body, re-tasking both T cells and myeloid cells. A third antibody therapy blocks a protein called granulocyte colony stimulating factor (G-CSF), which fuels immune suppression and drives resistance to vascular endothelial growth factor (VEGF) drugs.

A key partner is NanoVation Therapeutics, co-founded by lipid nanoparticle pioneer Pieter Cullis, whose delivery systems enabled the first Covid-19 vaccines. ME Therapeutics is using NanoVation’s nanoparticles to ferry its mRNA payloads to immune cells while avoiding the liver, a common stumbling block.

Preclinical work is still early. Studies in mice and non-human primates are scheduled through 2026, with the first regulatory applications expected late that year.

ME Therapeutics’ ambitions are big, but, like most start-ups in the biotechnology space, so are the risks. It is also betting on next-generation technologies, such as in vivo CARs, that have yet to be proven in people. Still, with immuno-oncology drugs now among the industry’s top sellers and combinations extending their reach, investors are watching.

“If you can reprogram the immune environment rather than chase each new tumor mutation, the potential is enormous,” says Dhanji.

The G-CSF antibody program is the most advanced, though whether it or the therapeutic mRNA program reaches the clinic first remains to be seen. There is a case for the latter: the timeline to “spin up” an mRNA drug for a specific cancer is relatively short, as little as six to 12 months, Dhanji explains.

ME Therapeutics’ approach also has transformative potential in CAR therapy, which typically involves genetically engineered T cells trained to hunt and destroy cancer. Used to combat blood cancers such as leukemia, lymphoma, and multiple myeloma, success rates can be upward of 80%. But the process requires a blood transfusion, which is uncomfortable, and costs between $500,000 and $1 million.

Using ME Therapeutics’ method, Dhanji says, could ultimately pull the price down toward that of traditional gold-standard cancer treatments, as well as leverage myeloid cells in addition to T cells. “There is a lot of potential in some of the work that we’re doing in the lab, preclinically right now, and we think we can advance to the clinic very quickly,” he says. “So now, it’s really a matter of deciding which program we want to prioritize.”

As with all small-cap biotech, funding is an ever-present requirement. Dhanji says the company’s current runway is long enough to fund the first candidate to initial meetings with the FDA or Health Canada. After that, further investment will be needed.

An industry partnership with a large drugmaker is possible but uncommon at this stage. Dhanji wants intellectual property patent-protected before any such discussions take place. “I think one of the challenges is that we need to be able to protect our IP before we actually go and have these conversations, as the space is relatively fluid,” he explains.

Dhanji is not without ambition and would like to emulate Genentech, the founding company of biotechnology. It may be difficult to repeat the San Francisco giant’s success, but it is the pioneer spirit he admires, when budgets were spared to solve real human problems, not the balance sheet metrics that fixate Big Pharma.

Yet Dhanji is also a realist. “I do have to run a business, and I take that responsibility very seriously. But what gets me out of bed in the morning, what motivates me, is the old researcher’s curiosity and the hope our work may make a difference.”

This story was featured in Canadian Securities Exchange Magazine.

Learn more about ME Therapeutics https://metherapeutics.com/.

Magazine

Canadian Securities Exchange Magazine: The Global Issue – Now Live!

Welcome to the latest issue of Canadian Securities Exchange Magazine, your source for in-depth stories of entrepreneurs from a wealth of different industries.

The global capital markets map is being redrawn in real time. Economies are facing an inflection point: never before has the world been more interconnected through technology and trade; however, geopolitical tensions and economic uncertainties have created new barriers to interoperability. Many CSE listed companies are showcasing what happens when innovation refuses to concede to complacency, demonstrating that entrepreneurial vision paired with strategic execution can transcend complex geographic constraints. 

In this issue of Canadian Securities Exchange Magazine, discover the stories of nine CSE listed companies taking on global challenges in defence, healthcare, technology, and beyond. Plus, WFE CEO Nandini Sukumar shares how the global network of exchanges enables innovation and sustainability around the world, and we spotlight National Stock Exchange of Australia Managing Director and CEO Max Cunningham.

The CSE listed companies featured in this issue include:

Check out The Global Issue of Canadian Securities Exchange Magazine here:

CSE Issuer Stories, Magazine

Disciplined, Systematic Development in Newfoundland’s Untapped Gold Frontier

Gold Hunter Resources (CSE:HUNT; OTCQB:HNTRF) is not just another junior explorer with a big land package. It is a team that delivered meaningful shareholder value in 2024 and is now returning to Newfoundland with a fully consolidated district, deep technical leadership, and a strategy rooted in data, geology, and discipline.

At the heart of the company’s plan is the Great Northern Project, a 26,000-hectare district-scale land package running along the Doucers Valley Fault. While nearly 500 historical drill holes exist, they are concentrated in just four small areas. In contrast, 18 gold-bearing trends remain virtually untested. The result is a rare mix of scale, infrastructure access, and near-term upside in one of North America’s most supportive mining jurisdictions.

In 2023, Gold Hunter sold its initial Newfoundland asset to FireFly Metals in a transaction valued at over $30 million. More than $25 million worth of FireFly shares were issued directly to Gold Hunter shareholders, creating immediate and tangible value during a quiet junior market.

But the exit was not the end of the story. Just 5 kilometres from the original ground, Gold Hunter began consolidating an even larger opportunity. Through more than 10 separate transactions with private holders and small operators, the company unified a 50-kilometre trend along the Doucers Valley Fault. This marked the first time this corridor has ever been controlled by a single entity.

The company’s success in quietly acquiring these projects ahead of better-capitalized competitors has set the foundation for something bigger.

The Great Northern Project follows a proven structural template: a major regional fault with multiple mineralized splays, hosted in rocks nearly identical to those at Equinox Gold’s Valentine Project.

“Although this is structurally complex like most mineralized gold systems, our approach is systematic,” says Chief Executive Officer Sean Kingsley. “Once you understand the controls, you can start stringing deposits together. It’s a classic string-of-pearls model.”

That model has worked well at Valentine. Starting with a small initial resource, it was built into a 5-million-ounce system with clear continuity and expanding scale. Gold Hunter sees Great Northern as following that same path, with a more advanced starting point thanks to nearly 500 legacy drill holes, robust geochemical coverage, and district-scale consolidation already complete.

Rather than rush into drilling, Gold Hunter spent three months in 2024 compiling the first full district-scale dataset ever assembled in this region. The team aggregated historic work from over a dozen sources, including past operators, government surveys, and private holders, into a single coherent exploration model.

The database includes more than 36,000 soil samples, 7,700 rock samples, 500 lake and stream sediment samples, 660 till samples, 5,700 mapped outcrops, multiple smaller geophysical surveys, and over 66,000 metres of historical drilling. That effort revealed high-priority trends that had previously fallen through the cracks due to fragmented ownership and limited budgets.

“Now that we’ve compiled the data, we’re layering in geophysics to take it further,” says Kingsley. “The VTEM survey we’re flying over the entire district will help us pinpoint new structural corridors, extensions of known zones, and areas that were never tested properly.”

Gold Hunter’s project is located in one of the most mining-friendly and accessible regions of Canada. Infrastructure is already in place, including hydroelectric power on site, highway access within walking distance, a mill located just over the ridge, and a deep-sea port facility just a few kilometres away.

“These are the things that matter when you’re looking to build value fast,” Kingsley says. “We don’t need to build roads, power lines, or ship ore across the country. We’re right where we need to be.”

In addition, Newfoundland and Labrador offers supportive permitting frameworks, experienced local workers, and a government eager to promote responsible resource development. These are factors that continue to attract serious exploration and development activity across the province.

Unlocking regional-scale gold systems takes more than ground. It takes people who understand how these systems behave.

Gold Hunter’s technical lead, Rory Kutluoglu, brings both geoscience and geophysics expertise and played a key role in Kaminak’s Coffee Gold deposit, which was acquired by Goldcorp for US$520 million. He sees Great Northern as another high-potential system, this time with infrastructure and historical drilling already in place.

On the ground, veteran Newfoundland geologists Tanya Tettelaar and David Copeland offer unmatched local knowledge. Tettelaar spent six years as exploration manager at Marathon Gold, helping advance Valentine through its critical growth phases. Copeland has worked directly on parts of the Great Northern land package for over a decade and was instrumental in building the Goldboro deposit, now part of NexGold.

“This is one of the strongest technical teams I’ve worked with,” says Kingsley. “We’ve got national-level discovery experience and local geological intuition coming together. That’s how you de-risk exploration.”

Kingsley himself has been active in Newfoundland and Labrador since the early 2010s and sees the province as one of the last places in North America where major new discoveries are still possible.

With a past win under its belt, a fully consolidated district, an expansive geological and geophysics dataset, and a proven technical team, Gold Hunter is positioned to help write the next chapter of Newfoundland’s gold story.

The company has completed its initial VTEM survey and is in the midst of ground truthing drill targets for 2025. Every metre will be guided by data. Every target will build on a district-wide vision.

“We’ve done the hard work. Acquisition, compilation, modelling, and survey execution,” says Kingsley. “Now it’s time to drill. And we know exactly where to start.”

This story was featured in Canadian Securities Exchange Magazine.

Learn more about Gold Hunter Resources https://goldhunterresources.com/.

CSE Issuer Stories, Magazine

Focused Portfolio and a Smart Business Model Give This Explorer Every Chance at Success

The Western United States has long been one of the world’s most attractive jurisdictions for mineral exploration. The Carlin Trend and other well-known districts provide the prospectivity, while local familiarity with mining and supportive policy give exploration companies comfort that they can realize value from any deposits they might discover.

Headwater Gold (CSE:HWG; OTCQB:HWAUF) is advancing multiple projects in two western states – Nevada and Idaho – and its team could not be happier with what it is seeing.

“There are certainly a lot of tailwinds for the mining industry in the western part of the U.S. right now,” Headwater Gold President and Chief Executive Officer Caleb Stroup tells Canadian Securities Exchange Magazine. “And that’s especially true in jurisdictions like Nevada that have a strong mining culture in existence already. The local communities understand mining, the permitting systems are in place, and we’re seeing signs of improvement in timelines, as directed by the current administration.”

Headwater’s business model blends the traditional approach of direct-funded discovery with a prospect generator strategy designed to broaden exploration exposure while minimizing shareholder dilution. 

“Our view is that, especially in early-stage exploration, you need to take a portfolio approach and have multiple targets that are being tested at any given time. That simply gives you a better probability for making a discovery,” Stroup explains.

The CEO also acknowledges the challenges for juniors in relying exclusively on public or private markets to raise capital for exploration. 

“There is a pool of capital in larger companies looking for good exploration ideas, especially in places like Nevada, which is one of the best, if not the best, mining jurisdictions in the world,” Stroup says.

“We chose to build something that was a combination of raising money ourselves to explore our 100% owned projects and leveraging partner-funded capital to advance more projects, to offer scale to our exploration and shareholders.”

For a company of its size, Headwater Gold’s lineup of partners is impressive. One of the most notable is its two-project deal in Nevada with Newmont Corporation, the world’s largest gold producer.

Originally signed with Australian producer Newcrest Mining, the agreement was carried forward following Newmont’s acquisition of Newcrest in 2023.

Under the arrangement, Newmont is earning into Spring Peak and Lodestar, two epithermal projects in Nevada’s Walker Lane Trend, which has attracted attention in recent years following a Tier 1 discovery made by AngloGold Ashanti at its Silicon Project.

Centerra Gold, a major gold producer, also became a key partner last year, taking a 9.9% equity stake in Headwater.  

The numbers behind Headwater’s partnerships are significant. Using Newmont’s earn-in deal for the Spring Peak project as an example, Stroup says that the company always starts with a minimum commitment.

At Spring Peak, this was US$5 million minimum in exploration work, as part of a $15 million Stage 1 earn-in for 51% ownership. If that threshold is reached, Newmont can earn up to 75% by completing a prefeasibility study and granting Headwater a royalty, specifically a 2% net smelter return (NSR) on staked ground or 1% on small third-party parcels, following an additional US$40 million in exploration work.

“These are fairly big dollar numbers, both in terms of the minimum exploration commitment but also the ongoing earn-in exploration structure,” Stroup says.

On July 22 of this year, Headwater signed a letter of intent with OceanaGold covering three projects in northern Nevada: TJ, Jake Creek, and Hot Creek. The deal includes a minimum spending commitment by OceanaGold of US$2.5 million across the projects in the first two years of the agreement. OceanaGold could earn 75% of the projects with total exploration spending of US$65 million, completion of prefeasibility studies, and the granting to Headwater of 1% NSRs.

In the case of both the Newmont agreement and the OceanaGold partnership, Headwater is the project operator, collecting a 10% management fee on all exploration work it carries out.

“That allows us to have fairly close technical control as to what’s taking place on the ground,” Stroup says. “It also provides a mechanism for us to fund a lot of our ongoing costs at the corporate level with that 10% management fee, resulting overall in a very low burn rate, which over the last couple of years has been nearly net neutral despite all the activity in the portfolio.”

With five projects currently under partnership, Headwater is also advancing its 100% owned projects. Two standout assets are Midas North in Nevada and Crane Creek in Idaho.

At Midas North, Headwater holds the northern end of the historic Midas Mining District. Immediately to the south of Headwater’s land package is the Midas mine complex, where over 2 million ounces of gold and over 25 million ounces of silver were extracted from high-grade epithermal veins by various operators between 1998 and 2019.

Despite its proximity to the past-producing mine, the property is largely untested. Headwater’s early drilling and geologic mapping have defined a preserved alteration cell, indicating a potentially intact epithermal system at depth. 

“There are some very interesting targets that are emerging and we think we really have a shot at a Midas-type discovery,” Stroup states. 

Meanwhile, at Crane Creek, Headwater sees similar overlooked potential. Located in western Idaho, the project features a 4-kilometre-long gold anomaly and historic drilling that returned several high-grade intercepts.

Headwater’s recent work has also identified a higher-grade vein system which was previously untested. Surface sampling has returned multiple samples exceeding 5 grams per tonne gold, suggesting the potential for a vein-hosted discovery, according to Stroup. 

With partner funding and internal targets lined up, Headwater is preparing for multiple drilling programs in the coming year.

Notably, Newmont-funded exploration is expected to kick off at the Lodestar project, located at the northern end of the Aurora Mining District and adjoining Spring Peak. 

“This is the target area that we’ve been developing for the last couple of years now and remains probably the highest-priority undrilled target in the district, in my view at least,” Stroup says. “We’re waiting for one final permit to get going this fall here, and that’s progressing through. So that’ll be a good piece of news to watch for as that program develops.”

As part of its newly announced partnership with OceanaGold, it is expected that drilling will commence at the TJ project in the latter half of 2025. This will bring Headwater’s partner-funded drill programs to at least two by year-end. 

Behind Headwater’s success is a team of veteran geologists with experience in both major and junior exploration.

Stroup himself spent years in the field with Kinross Gold before founding Headwater. Chairman Alistair Waddell held senior roles at Kinross and has decades of experience in global gold exploration. The company recently added Fraser MacCorquodale, former Global Head of Exploration at Newcrest, to its board.

This technical credibility has been a key factor in building trust with major partners, Stroup believes.

“Our experience with the majors at the corporate level is in large part the reason why we’ve been able to build their trust and establish so many partnerships. With these earn-in partnerships, we can give shareholders a great shot at a new discovery and exploration upside but minimize the dilution required to get there.”

This story was featured in Canadian Securities Exchange Magazine.

Learn more about Headwater Gold at https://headwatergold.com/.

CSE Issuer Stories, Magazine

High-Grade Gold Projects in Eastern Canada Form Basis for Resource Expansion Plan

It’s a good time to be in the gold exploration business, and even more so if you have projects in safe jurisdictions, given the current geopolitical environment. That said, exploration brings its fair share of challenges: you need a special combination of project quality, personnel, and the knack to create your own good fortune in order to come out on top.

From that perspective, Exploits Discovery (CSE:NFLD; OTCQB:NFLDF) seems built for success. Focusing on well-known mining districts in Eastern Canada and projects that have yielded some truly outstanding drill results, Exploits quickly put together an initial historical resource base and is advancing a plan to expand it in the shortest time possible.

With an accomplished team, healthy treasury, and the backing of one of the most successful investors in the history of mining, the future looks bright.

Exploits Discovery Chief Executive Officer Jeff Swinoga spoke with Canadian Securities Exchange Magazine  about developments to date and where he sees the company going over the near and medium terms.

Let’s begin with an overview of your objectives at Exploits Discovery and where you stand with progress thus far.

Our goal is to build Exploits into a premier gold exploration company. We’ve transformed the company from having no gold ounces to a historical resource of nearly 700,000 ounces in under two months.

Exploits’ projects are located in three top-tier mining regions: Ontario, Québec, and Newfoundland. We’ve structured our portfolio to combine historic gold resources with meaningful exploration upside. The goal is to deliver sustained growth, long-term shareholder value, and leadership in the sector.

Having strong cash reserves and the discipline to carry out proper due diligence gave us the agility to seize these opportunities quickly.

Let’s begin our look at the projects with the Hawkins Gold Project in Ontario. Why is Hawkins exciting for your team?

Hawkins is a district-scale opportunity. We have an option to acquire 100% of the project, which sits on a 60-kilometre greenstone belt geologically similar to the Hemlo deposit. The Hemlo Mine is one of Canada’s most prolific, with over 21 million ounces of gold produced. Hawkins currently has a historic inferred resource of roughly 328,000 ounces at 1.65 grams per tonne gold, and mineralization is open along strike and at depth.

Our focus is on permitting, prospecting, stripping, and geophysical surveys that will enhance the understanding of several prospective areas and could lead to priority future drill targets and drilling to expand that resource. Current prospective areas include both east and west along strike of the historic McKinnon Zone and multiple locations that have reported historic gold showings.  

You’re also active in Québec. What’s the strategy there?

Québec offers both scale and flexibility. We have three drill-ready properties: Benoist, Wilson, and Fenton. All are located in established mining districts with excellent infrastructure.

At Benoist, we’ve got two gold zones with historic indicated resources of around 134,400 ounces at 2.87 grams per tonne gold and inferred resources of 107,000 ounces at 2.3 grams per tonne. That project alone has room to grow.

Wilson, just 15 kilometres from Benoist, covers 1,750 hectares and hosts three known gold zones. Previous drilling traced mineralization over 700 metres of strike, 350 metres of width, and 300 metres of depth with some historic intercepts up to 43.3 grams per tonne gold.

Fenton is a high-grade story. We’re looking at 12 gold zones across 671 hectares, with a non-compliant historical estimate of 426,173 tonnes grading 4.66 grams per tonne gold. One standout result showed 356 grams per tonne gold over narrow widths. We’re progressing through permitting and lining up trenching, sampling, and geophysical work ahead of drilling.

And in Newfoundland?

We’ve secured 100% owned claims along the Appleton Fault Zone and Dog Bay Line, right next to New Found Gold’s recent 2-million-ounce discovery. It’s a very strategic position we have created.

We’ve already identified two zones with high-grade assays. Horseshoe returned 38.2 grams per tonne gold over 2.8 metres, and Saddle yielded 67.55 grams per tonne gold over 3.3 metres with visible gold. Our regional till sampling shows gold grain counts well above background levels, highlighting strong discovery potential.

What’s ahead for the second half of 2025?

On each of our properties, we’re advancing permitting, prospecting, stripping, and geophysical surveys that will enhance the understanding of several prospective areas and could lead to priority future drill targets. We will also be preparing drill programs at our highest-priority targets. The plan is to deliver drilling results later this summer or early autumn. Those results will feed into updated resource estimates.

We’re also evaluating joint ventures for non-core assets to sharpen our focus on the highest-grade opportunities.

What sets Exploits Discovery apart in a crowded junior mining space?

It comes down to four things: scale, location, financial flexibility, and upside.

We have a combined historical resource base of approximately 680,000 ounces of gold across four projects in some of Canada’s top-tier mining jurisdictions, including Ontario and Québec. All of our assets are in established structural gold belts with strong infrastructure and a history of production. This gives us a de-risked, geographically diverse foundation.

As I said earlier, and this should never be underestimated, we’re also well-funded and we’re positioned to move quickly on opportunities. That strength allowed us to secure multiple high-quality projects in a matter of weeks.

Another key point is our valuation. We’re currently trading at around $6 per ounce of gold in the ground, while peers typically trade between $40 and $50 per ounce. And there’s multiple potential re-rating catalysts ahead, including drill results and possible resource updates.

And finally, the upside. All of our projects are open at depth and along strike, with multiple drill-ready targets. Our plan is straightforward: build ounces, expand resources, and unlock value. Whether that’s through organic growth, joint ventures, or strategic combinations, we’re structurally set up to grow.

Exploits has a well-known backer in Eric Sprott. What does that mean for the company?

Eric Sprott owning 14% of our shares is a strong vote of confidence in our team, our strategy, and our assets. His involvement signals to the market that we’re building something with real potential.

Tell us a bit about yourself and the team.

I’ve spent about 27 years in mining, starting at Barrick Gold, then moving on to CFO roles at Hudbay Minerals and North American Palladium. I also served as CEO at First Mining Gold and was the national mining leader at EY. I’ve worked on projects all over the world, from Argentina and Ghana to Mexico and Canada.

Shanda Kilborn, who leads corporate development and investor relations, has nearly two decades of experience with junior miners, including Abitibi Royalties. Our technical advisor, Dr. Natalie Pietrzak-Renaud, brings over 20 years of multi-commodity exploration experience across gold, rare earth elements, diamonds, and base metals. She holds a PhD in Geology from Western University and is a registered professional geoscientist in Ontario, the Northwest Territories, and Nunavut.

What’s the long-term outlook for Exploits Discovery?

It’s simple. We are focused on growing ounces and improving grade, new potential acquisitions, and new gold discoveries.

As I said at the start, we have established a solid foundation to grow our company for the benefit of our shareholders.

This story was featured in Canadian Securities Exchange Magazine.

Learn more about Exploits Discovery at https://www.exploitsdiscovery.com/.